Viewing Study NCT03085992


Ignite Creation Date: 2025-12-24 @ 3:20 PM
Ignite Modification Date: 2026-01-18 @ 2:24 AM
Study NCT ID: NCT03085992
Status: COMPLETED
Last Update Posted: 2018-03-14
First Post: 2016-06-08
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer
Sponsor: Azienda Ospedaliero, Universitaria Pisana
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Rectal Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None rectal cancer View
None FOLFOXIRI View
None bevacizumab View
None trust View